When targeting problem proteins involved in causing or spreading disease, a drug will often clog up a protein’s active site so it can’t function and wreak havoc.
Meta Title: “ImmunityBio Inc Files Patent for Cross-Reactive SARS-CoV2 Vaccine Composition
Share this article According to GlobalData’s company profile on ImmunityBio, was a key innovation area identified from patents. ImmunityBio‘s grant share as of February 2024